Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer (CAMARA)

Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer

Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer

In oncology, anemia is a frequent symptom, leading to complication of patient management for, more or less, a long term but often poorly evaluated by medical teams. In oncology, anemia is induced by multiple causes. Iron deficiency appears to be a leading cause of anemia, especially in people with solid cancer. Iron deficiency is characterized by a low level of iron . Iron is a trace element required for life. It is a major component of hemoglobin allowing the transport of oxygen in red blood cells. There are in fact 2 types of iron deficiency: an absolute iron deficiency with a deficiency of true iron and a functional iron deficiency. Since end of January 2014, intravenous iron-based injections have been reclassified for cancer patients at ICO Paul Papin. The monitoring of iron deficiency with or without anemia is currently done in our institute, the ICO-Paul Papin. There is a procedure for the management of anemia with or without iron deficiency but there is still no traceability of treatments performed, their compliance or even their impact on the rate hemoglobin and the quality of life of patients during their treatment. This observatory also makes it possible to evaluate the impact of this treatment on the quality of life of the patients and thus allows them a personalized care of the tiredness during their treatment

The study is for patients with iron deficiency and / or anemia during treatment for cancer These patients will receive ferinject. Patients will perform functional assessments and complete quality of life questionnaires, when the ferinject will be injected, then at 1 month and 6 months. Patients will be followed for 6 months in the study

Evaluation of the quality of life of patients with iron deficiency with or without anemia during treatment for their cancer

Absolute iron deficiency is defined by a ferritin level <300 μg / L and a transferrin saturation coefficient <20%.

Functional iron deficiency is defined by a ferritin level <800 μg / L and a Transferrin Saturation Coefficient <20%.

Symptomatic anemia is defined as hemoglobin <12 g / dL associated with pallor and anoxic functional symptoms

The diagnosis of malnutrition will be done by calculating BMI (<18.5 si - 70 years old and <21 from 70 years old)

Inclusion Criteria: Age ≥ 18 years Patient with cancer regardless of the location Patient with specific treatment (chemotherapy +/- targeted therapy and / or radiotherapy, hormone therapy or surgery) Patient with Functional Iron Deficiency or absolute with or without anemia Having given written informed consent prior to any procedure related to the study. Exclusion Criteria: Patient in a palliative situation not receiving specific treatment for their cancer Patient is willing and able to comply with the protocol for the duration of the study including all scheduled treatment, visits and examinations Patient with myeloproliferative disease Contraindication to treatments for iron deficiency and / or anemia Pregnant woman, parturient or nursing mothers Patient has no valid health insurance Disorder precluding understanding of trial information or informed consent

Gluszak C, de Vries-Brilland M, Seegers V, Baroin C, Kieffer H, Delva R, Cornuault-Foubert D. Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study). Oncologist. 2022 Apr 5;27(4):328-333. doi: 10.1093/oncolo/oyac005.